OKYO Pharma to Host KOL Event for OK-101 Phase 2 Data
Ticker: OKYO · Form: 6-K · Filed: Mar 21, 2024 · CIK: 1849296
Sentiment: neutral
Topics: clinical-trial-update, biotech, event-announcement
TL;DR
OKYO Pharma hosting KOL event April 9th to discuss OK-101 Phase 2 efficacy data.
AI Summary
OKYO Pharma Ltd announced on March 21, 2024, that it will host a Key Opinion Leader (KOL) event on April 9th, 2024, at 12:00 PM ET. The event will focus on discussing comprehensive efficacy data from the Phase 2 trial of their drug OK-101 for dry eye disease.
Why It Matters
This event provides an opportunity for investors and medical professionals to gain deeper insights into the efficacy of OK-101, a key drug candidate for OKYO Pharma, potentially influencing future investment and clinical development decisions.
Risk Assessment
Risk Level: medium — The company is discussing Phase 2 trial data, which is a critical stage, and the success or failure of this trial will significantly impact the company's future prospects.
Key Numbers
- April 9th, 2024 — KOL Event Date (Date for discussing Phase 2 trial data)
- 12:00 PM ET — KOL Event Time (Time for discussing Phase 2 trial data)
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- OK-101 (drug) — Drug candidate for Phase 2 trial
FAQ
What specific efficacy data from the Phase 2 trial of OK-101 will be discussed at the KOL event?
The filing states that comprehensive efficacy data from the Phase 2 trial of OK-101 will be discussed, but does not specify the exact data points.
Who are the Key Opinion Leaders (KOLs) that will be presenting or participating in the event?
The filing does not name the specific Key Opinion Leaders who will be involved in the event.
What is the primary indication for the drug OK-101?
The filing indicates that OK-101 is being tested in a Phase 2 trial for dry eye disease.
What is the expected outcome or significance of this KOL event for OKYO Pharma?
The event is intended to provide an in-depth discussion of the efficacy data, which could influence investor perception and future development strategies for OK-101.
Where is OKYO Pharma Ltd's principal executive office located?
OKYO Pharma Ltd's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Stats: 369 words · 1 min read · ~1 pages · Grade level 14.9 · Accepted 2024-03-21 07:00:34
Filing Documents
- form6-k.htm (6-K) — 23KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-010725.txt ( ) — 54KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: March 21, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated March 21, 2024 4